[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fractyl Health Inc (GUTS)

Fractyl Health Inc (GUTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,991
  • Shares Outstanding, K 158,649
  • Annual Sales, $ 0 K
  • Annual Income, $ -140,950 K
  • EBIT $ -93 M
  • EBITDA $ -92 M
  • 60-Month Beta 2.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings $-0.13 on 05/12/26
  • Next Earnings Date 08/10/26 [AMC]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 3
  • High Estimate $-0.14
  • Low Estimate $-0.16
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) +71.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6722 +4.08%
on 07/31/26
1.0200 -31.41%
on 07/15/26
-0.0964 (-12.11%)
since 07/07/26
3-Month
0.6500 +7.63%
on 06/05/26
1.0300 -32.08%
on 05/14/26
-0.0485 (-6.48%)
since 05/07/26
52-Week
0.3772 +85.47%
on 02/05/26
2.4450 -71.39%
on 12/12/25
-0.2731 (-28.08%)
since 08/07/25

Most Recent Stories

More News
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches...

GUTS : 0.6996 (+1.83%)
Fractyl Health to Participate in Upcoming Investor Events

BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches...

GUTS : 0.6996 (+1.83%)
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline...

GUTS : 0.6996 (+1.83%)
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure 5.3% mean weight change observed with Revita (n=15); published third-party...

GUTS : 0.6996 (+1.83%)
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches...

GUTS : 0.6996 (+1.83%)
Fractyl Health Q1 Earnings Call Highlights

Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments...

GUTS : 0.6996 (+1.83%)
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing...

GUTS : 0.6996 (+1.83%)
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for...

GUTS : 0.6996 (+1.83%)
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat...

GUTS : 0.6996 (+1.83%)
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in...

GUTS : 0.6996 (+1.83%)

Business Summary

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Fractyl Health is based in Lexington, MA.

See More

Key Turning Points

3rd Resistance Point 0.7462
2nd Resistance Point 0.7331
1st Resistance Point 0.7163
Last Price 0.6996
1st Support Level 0.6864
2nd Support Level 0.6733
3rd Support Level 0.6565

See More

52-Week High 2.4450
Fibonacci 61.8% 1.6551
Fibonacci 50% 1.4111
Fibonacci 38.2% 1.1671
Last Price 0.6996
52-Week Low 0.3772

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.